Abu-Fadel MS - Search Results

1

Is risk factor control and guideline-based medical therapy optimal in patients with nonobstructive coronary artery disease? A Veterans Affairs study.

Dasari TW, Golwala H, Koehler M, Wayangankar S, Pakala A, Schechter E, Lozano P, Abu-Fadel MS, Latif F, Thadani U. Dasari TW, et al. Am J Med Sci. 2013 May;345(5):339-42. doi: 10.1097/MAJ.0b013e31825c6951. Am J Med Sci. 2013. PMID: 23044654

2

Coronary slow flow--prevalence and clinical correlations.

Hawkins BM, Stavrakis S, Rousan TA, Abu-Fadel M, Schechter E. Hawkins BM, et al. Circ J. 2012;76(4):936-42. doi: 10.1253/circj.cj-11-0959. Epub 2012 Feb 1. Circ J. 2012. PMID: 22293446 Free article.

3

Embolic protection device use and outcomes in patients receiving saphenous vein graft interventions--a single-center experience.

Golwala H, Hawkins BM, Stavrakis S, Abu-Fadel MS. Golwala H, et al. J Invasive Cardiol. 2012 Jan;24(1):1-3. J Invasive Cardiol. 2012. PMID: 22210580 Free article.

4

A new era of antithrombotic therapy in patients with atrial fibrillation.

Golwala H, Dib C, Tafur A, Abu-Fadel MS. Golwala H, et al. Am J Med Sci. 2012 Aug;344(2):128-35. doi: 10.1097/MAJ.0b013e3182429b1e. Am J Med Sci. 2012. PMID: 22245946 Review.

5

Clinical safety of bivalirudin in patients undergoing carotid stenting.

Cogar BD, Wayangankar SA, Abu-Fadel M, Hennebry TA, Ghani MK, Kipperman RM, Chrysant GS. Cogar BD, et al. J Invasive Cardiol. 2012 May;24(5):202-5. J Invasive Cardiol. 2012. PMID: 22562912 Free article.

6

Rapidly evolving coronary aneurysm in a patient with rheumatoid arthritis.

Pappy R, Wayangankar S, Kalapura T, Abu-Fadel MS. Pappy R, et al. Cardiol Res Pract. 2011 Feb 21;2011:659439. doi: 10.4061/2011/659439. Cardiol Res Pract. 2011. PMID: 21403892 Free PMC article.

7

Hemorrhagic and ischemic outcomes after bivalirudin versus unfractionated heparin during carotid artery stenting: a propensity score analysis from the NCDR.

Wayangankar SA, Abu-Fadel MS, Aronow HD, Kennedy KF, Gupta R, Yeh RW, Gray WA, Rosenfield K, Hennebry TA. Wayangankar SA, et al. Circ Cardiovasc Interv. 2013 Apr;6(2):131-8. doi: 10.1161/CIRCINTERVENTIONS.112.974857. Epub 2013 Mar 26. Circ Cardiovasc Interv. 2013. PMID: 23532554

8

Plaque Regression and Endothelial Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER).

Banerjee S, Luo P, Reda DJ, Latif F, Hastings JL, Armstrong EJ, Bagai J, Abu-Fadel M, Baskar A, Kamath P, Lippe D, Wei Y, Scrymgeour A, Gleason TC, Brilakis ES. Banerjee S, et al. Circ Cardiovasc Interv. 2020 Aug;13(8):e008933. doi: 10.1161/CIRCINTERVENTIONS.119.008933. Epub 2020 Aug 14. Circ Cardiovasc Interv. 2020. PMID: 32791950 Clinical Trial.

9

Fluoroscopy vs. traditional guided femoral arterial access and the use of closure devices: a randomized controlled trial.

Abu-Fadel MS, Sparling JM, Zacharias SJ, Aston CE, Saucedo JF, Schechter E, Hennebry TA. Abu-Fadel MS, et al. Catheter Cardiovasc Interv. 2009 Oct 1;74(4):533-9. doi: 10.1002/ccd.22174. Catheter Cardiovasc Interv. 2009. PMID: 19626694 Clinical Trial.

10

A new era for antiplatelet therapy in patients with acute coronary syndrome.

Dib C, Hanna EB, Abu-Fadel MS. Dib C, et al. Am J Med Sci. 2010 Nov;340(5):407-11. doi: 10.1097/MAJ.0b013e3181ee5bfb. Am J Med Sci. 2010. PMID: 20818228 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

66 results

Search Page